🔴 Crispr Therapeutics is trading 4% down today as oil prices and Treasury yields rise

Crispr Therapeutics is trading 4.01% lower at $56.66 as U.S. equities weaken amid higher oil prices, rising Treasury yields, and softer risk appetite on September 23, 2026.

• The Nasdaq is down 1.00%, while the S&P 500 is down 0.56%, creating a challenging backdrop for growth-oriented biotechnology stocks.
• No fresh company-specific catalyst was identified; recent coverage remains focused on pipeline updates and analyst optimism.